ClinicalTrials.gg

Program

rimegepant

Also written as “Rimegepant”, “BMS-927711 (CGRP Antagonist)” and “Rimegepant (PF-07899801)”.

Its studies are mostly in Migraine Disorders · Nasal Polyps · Trigeminal Neuralgia · Temporomandibular Joint Disorders, led by Pfizer.

Furthest: phase 4, since Jan 12, 202227 company-led studies, 8 open or runningNext primary completion: Nov 29, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer278 open or runningphase 4since Jan 12, 2022Sep 7, 2011Nov 29, 2026phase 3 · NCT06641466

Also a collaborator on its studies: bioshin-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Sep 7, 2011.

  1. Nov 19, 2021Phase 3 study in Migraine DisordersNCT05156398 · 640 planned · United States, Canada, France and more
  2. Jan 12, 20222 phase 4 studies in Migraine DisordersNCT05207865, NCT05217927
  3. Jan 31, 2022Phase 3 study in Chronic Rhinosinusitis (CRS) With and Without Nasal PolypsNCT05248997 · 261 enrolled · United States
  4. Feb 21, 2022Phase 3 study in Temporomandibular Joint DisordersNCT05262517 · 126 enrolled · United States
  5. Mar 23, 2022Phase 3 study in Migraine DisordersNCT05371652 · 241 enrolled · China
  6. May 27, 20222 phase 3 studies in Migraine DisordersNCT05399485, NCT05399459
  7. Aug 18, 20222 phase 4 studies in Migraine DisordersNCT05509400, NCT05518123
  8. Mar 30, 2023Phase 3 study in Migraine DisordersNCT05810038 · 787 enrolled · China
  9. Sep 24, 2024Phase 3 study in Migraine DisordersNCT06616194 · 636 enrolled · United States, Canada, China and more
  10. Oct 11, 2024Phase 3 study in Menstrual MigraineNCT06641466 · 723 planned · United States, Argentina, Canada and more
  11. May 20, 2026Phase 4 study in Acute Treatment of MigraineNCT07609914 · 400 planned · United States, Israel
  12. Jun 29, 2026Phase 4 study in Migraine DisordersNCT07685769 · 60 planned · India
  13. Jul 22, 2026Phase 3 study in Preventive Treatment of MigraineNCT07729462 · 400 planned · United States, Israel
  14. Oct 23, 2026Primary completion moved from 2028-08-19 to 2030-02-26Date moved laterphase 3 · +18 months · NCT06616194

Ahead

  1. Nov 29, 2026Primary completion: phase 3 study in Menstrual MigraineNCT06641466
  2. Jan 4, 2028Primary completion: phase 4 study in Migraine DisordersNCT07685769
  3. Jun 7, 2028Primary completion: phase 4 study in Acute Treatment of MigraineNCT07609914
  4. Oct 21, 2028Primary completion: phase 3 study in Preventive Treatment of MigraineNCT07729462

TargetBeta

CALCRL →read by rule
“Calcitonin gene-related peptide type 1 receptor antagonist; Calcitonin gene-related peptide type 1 receptor antagonist”ChEMBL 37, by rule

Other programs on CALCRL

ProgramCompanyFurthest phaseStudies
atogepantruleAbbViephase 419
ubrogepantruleAbbViephase 413
zavegepantrulePfizerphase 313

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07729462Preventive Treatment of Migraine · United States, Israel3RecruitingOct 21, 2028400
NCT07685769Migraine Disorders · India4RecruitingJan 4, 202860
NCT07609914Acute Treatment of Migraine · United States, Israel4RecruitingJun 7, 2028400
NCT06641466Menstrual Migraine · United States, Argentina, Canada and more3RecruitingNov 29, 2026723
NCT06616194Migraine Disorders · United States, Canada, China and more3Active, not recruitingFeb 26, 2030636
NCT05810038Migraine Disorders · China3CompletedAug 25, 2025787
NCT05518123Migraine Disorders · United States, Australia, Austria and more4CompletedMar 31, 2025962
NCT05509400Migraine Disorders · United States, Australia, Austria and more4CompletedMar 10, 2025813
NCT05399485Migraine Disorders · Japan3CompletedJan 18, 2024496
NCT05399459Migraine Disorders · Japan3CompletedJan 19, 2024897
NCT05371652Migraine Disorders · China3CompletedFeb 6, 2024241
NCT05262517Temporomandibular Joint Disorders · United States3TerminatedMay 18, 2023126
NCT05248997Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps · United States3CompletedMar 11, 2024261
NCT05217927Migraine Disorders · United States, Austria, Canada and more4CompletedOct 22, 20241,415
NCT05207865Migraine Disorders · United States4CompletedJul 2, 2024441
NCT05156398Migraine Disorders · United States, Canada, France and more3RecruitingMar 27, 2029640
NCT04743141Migraine Disorders · United States, Poland, Spain3RecruitingJul 31, 2030600
NCT04649242Migraine Disorders · United States, Canada, China and more3RecruitingJan 9, 20292,100
NCT04574362Migraine Disorders · China, Korea, Republic of3CompletedNov 24, 20211,648
NCT03941834Trigeminal Neuralgia · United States2TerminatedMay 11, 202365
NCT03732638Migraine Disorders · United States3CompletedDec 10, 20191,590
NCT03461757Migraine Disorders · United States3CompletedOct 8, 20181,811
NCT03266588Migraine Disorders · United States3CompletedJul 15, 20193,019
NCT03237845Migraine Disorders · United States3CompletedJan 25, 20181,499
NCT03235479Migraine Disorders · United States3CompletedJan 21, 20181,485
NCT01445067Migraine Disorders · United States1CompletedSep 201248
NCT01430442Migraine Disorders · United States2CompletedMay 20121,026

How it is read

Names in the registry

  • “Rimegepant”, 21 entries
  • “BMS-927711 (CGRP Antagonist)”, 2 entries
  • “Rimegepant (PF-07899801)”, 1 entry
  • “Rimegepant/BHV3000”, 1 entry
  • “Rimegepant 75 mg ODT”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.